✦ LIBER ✦

A phase I study of ifosfamide with mesna given daily for 3 consecutive days to children with malignant solid tumors

✍ Scribed by Charles B. Pratt; William H. Meyer; Edwin C. Douglass; Laura Bowman; Judith Wilimas; Judith Ochs; Neyssa Marina; Loraine Avery; Elizabeth I. Thompson

Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 431 KB
Volume: 71
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19930601)71:11<3661::aid-cncr2820711131>3.0.co;2-w

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I study of ifosfamide given on a

A phase I study of ifosfamide given on alternate days to treat children with brain tumors

✍ Charles B. Pratt; Edwin C. Douglass; Richard Heideman; Loraine Avery; Stewart J. 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 395 KB 👁 1 views

A Phase I study of raltitrexed and pacli

A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors

✍ Everett E. Vokes; Boon C. Goh; Donna Bertucci; Nicholas J. Vogelzang; Sridhar Ma 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB 👁 1 views

## BACKGROUND. Raltitrexed is a novel thymidylate synthase inhibitor with single agent activity in colorectal, nonsmall cell lung, and breast carcinomas. The recommended Phase II dose of raltitrexed administered as a single agent is 3 mg/m 2 every 3 weeks. Paclitaxel also has a broad spectrum of a

Phase I study to evaluate multiple regim

Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors : A potential broadly active regimen for advanced solid tumor malignancies

✍ Sridhar Mani; Nicholas J. Vogelzang; Donna Bertucci; Walter M. Stadler; Richard 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

A Phase I study of granulocyte-macrophag

A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors : A report of the Children's Cancer Group

✍ Mitchell S. Cairo; Mark D. Krailo; Joel A. Weinthal; Rita Secola; Sharon Bergero 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 2 views

## Background: This phase i trial was developed to determine the safety, biologic activity, and effects on hematopoietic recovery of pixy321 following ifosfamide, carboplatin, and etoposide chemotherapy for children with recurrent or refractory solid tumors. ## Methods: Children (age < 22 years a